Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18949157 | 1.00 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CGAANOS3 | |
| SCHEMBL18949217 | 1.00 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CGAANOS3 | |
| SCHEMBL18949167 | 1.00 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CGAANOS3 | |
| SCHEMBL10100731 | 0.98 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CGAANOS3 | |
| SCHEMBL12903040 | 0.94 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CGAANOS3 | |
| SCHEMBL19682255 | 0.83 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CGAANOS3 | |
| SCHEMBL18949084 | 0.83 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CCDK5CDK5R1 | |
| SCHEMBL18949087 | 0.83 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CCDK5CDK5R1 | |
| SCHEMBL12398688 | 0.82 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL22353570 | 0.80 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262845-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262845-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | ADRA2A 3284/4885ADRA2B 2351/4885ADRA2C 2909/4885 |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | ADRA2A 3601/4885ADRA2B 3360/4885ADRA2C 3339/4885 |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | ADRA2A 3601/4885ADRA2B 3360/4885ADRA2C 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.